Echocardiographic Changes With Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy

Recommendations for Chamber Quantification: A Report from the American Society of Echocardiography’s Guidelines and Standards Committee and the Chamber Quantification Writing Group, Developed in Conjunction with the European Association of Echocardiography, a Branch of the European Society of Cardiology

Roberto M. Lang, Michelle Bierig, Richard B. Devereux et al. · Journal of the American Society of Echocardiography · 2005 · 11.3K citations

Medicine, Cardiology, Clinical Cardiology +14

2023 ESC Guidelines for the management of cardiomyopathies

Elena Arbelo, Alexandros Protonotarios, Juan R. Gimeno et al. · European Heart Journal · 2023 · 2.4K citations · Full text

Medicine, Cardiology, Internal Medicine +12

Mavacamten for treatment of symptomatic obstructive hypertrophic cardiomyopathy (EXPLORER-HCM): a randomised, double-blind, placebo-controlled, phase 3 trial

Iacopo Olivotto, Artur Oręziak, Roberto Barriales‐Villa et al. · The Lancet · 2020 · 1.2K citations · Full text

Medicine, Cardiology, Pharmacotherapy +6

Hypertrophic Cardiomyopathy Is Predominantly a Disease of Left Ventricular Outflow Tract Obstruction

Martin S. Maron, Iacopo Olivotto, Andrey G. Zenovich et al. · Circulation · 2006 · 1.1K citations

Medicine, Cardiology, Internal Medicine +13

2020 AHA/ACC Guideline for the Diagnosis and Treatment of Patients With Hypertrophic Cardiomyopathy

Steve R. Ommen, Seema Mital, Michael A. Burke et al. · Journal of the American College of Cardiology · 2020 · 682 citations

Medicine, Cardiology, Internal Medicine +13